Evommune, Inc. (NYSE:EVMN) Given Consensus Rating of “Buy” by Brokerages

Shares of Evommune, Inc. (NYSE:EVMN) have received a consensus recommendation of “Buy” from the seven research firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $39.3333.

A number of brokerages have recently weighed in on EVMN. Leerink Partnrs raised Evommune to a “strong-buy” rating in a research note on Monday, December 1st. Leerink Partners started coverage on Evommune in a report on Monday, December 1st. They set an “outperform” rating and a $42.00 target price for the company. Morgan Stanley assumed coverage on shares of Evommune in a research note on Monday, December 1st. They set an “overweight” rating and a $36.00 price target on the stock. Wall Street Zen raised shares of Evommune from a “sell” rating to a “hold” rating in a research report on Sunday, December 14th. Finally, William Blair began coverage on shares of Evommune in a report on Monday, December 1st. They issued an “outperform” rating for the company.

Evommune Price Performance

Evommune stock opened at $17.59 on Friday. Evommune has a 1 year low of $13.89 and a 1 year high of $24.03.

Evommune (NYSE:EVMN) last posted its earnings results on Thursday, December 11th. The company reported ($8.07) earnings per share for the quarter, missing the consensus estimate of ($6.58) by ($1.49). The company had revenue of $10.00 million for the quarter, compared to analysts’ expectations of $10.00 million.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.